Gilead Needs Insurers to Cover New HIV Prevention Shot. CVS Isn’t Paying. Executives at Gilead Sciences, the biotech behind a ...

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

CVS is opting against covering a twice-yearly injectable HIV prevention drug, drawing criticism from advocates who are ...

CVS Health, one of the nation’s largest pharmacy benefit managers, has declined to cover Gilead’s newly FDA-approved HIV ...

CVS Health will not cover Gilead's Yeztugo, generic name lenacapavir (LEN), citing "clinical, financial, and regulatory ...

The owner of the United States' largest pharmacy benefit manager (PBM) is declining to cover Gilead Sciences’ long-acting HIV ...

At the International AIDS Society meeting this year, a young woman from South Africa spoke. She is the first Black woman from ...

Gilead Sciences Inc. Chief Executive Officer Daniel O’Day said the company’s new HIV prevention drug Yeztugo should be able ...

CVS Health will not add Gilead Sciences' new HIV prevention drug to its commercial plans for now, despite the medicine's ...

Gilead officials lauded the FDA's approval of lenacapavir, which has been studied and developed over nearly two decades. "We now have a very real opportunity to end the HIV epidemic," said Daniel ...

Lenacapavir is already approved as a twice-yearly antiretroviral treatment for people with multi-drug resistant HIV (which costs $42,250 for the first year of treatment and $39,000 each year after ...

Gilead is prioritizing registering the drug in 18 countries with high HIV incidence rates, including Ethiopia, Kenya, Mozambique, Nigeria, Rwanda, South Africa, Uganda, Zimbabwe, Philippines ...